BioBusiness

Madison Dearborn Partners will acquire a majority ownership position in CDMO Alcami.

By minding gaps in industry knowledge, bio/pharma companies can avoid development pitfalls.

Barriers impede biosimilar market entry into the United States despite the Biologics Price Competition and Innovation Act.

Takeda expands its global and therapy base with announced acquisition of Shire.

Smaller review divisions will bring experts closer to decision processes and reduce bottlenecks, FDA leaders say.

While technology promises advances for healthcare, a skilled workforce is needed to deliver on the potential.

Global investment firm Advent to acquire and invest in Sanofi’s European generics business, Zentiva, to boost its position in European market.

The transaction is part of Merck KGaA’s strategy to actively shape its product portfolio and focus on innovation-driven business.

The biopharmaceutical firm has chosen Rhode Island as the site of its next-generation biomanufacturing plant, which will offer flexibility, speed, and efficiency.

More diversified therapies and tighter payer budgets will challenge bio/pharma companies to think outside the industry.

The company’s close communication with customers has enabled it to bring advanced pipetting products to market.

The acquisition strengthens Celgene’s position in the global cellular immunotherapy space.

Takeda is considering approaching Shire with a possible offer.

In a $13-billion transaction, GSK will purchase Novartis’ share of the Consumer Healthcare Joint Venture.

The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.

A different perspective on controlling fixed costs of biomanufacturing, based on know-how from other industries, provides a competitive edge, says the CEO of Samsung BioLogics.

The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.

New programs and initiatives by industry examine rising healthcare costs.

The NECC supervisory pharmacist at the center of the 2012 fungal meningitis outbreak was sentenced to 8 years in prison.

Frustrated with high costs and drug shortages, hospitals adopt a DIY approach.

The latest continuing resolution funds the government for three weeks.

Non-essential activities and new regulatory submissions are on hold until a federal government funding agreement is reached.

Frustrated with chronic shortages and high costs, hospitals form their own generic drug company.

Scientific advances and renewed investment may infuse biopharma for growth.

BioPharm International will mark 30 years of biopharma industry progress and challenges in 2018.